Searched for
CIPLA BIOSIMILAR PRODUCT
These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...- These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- US biosimilar norms to keep local drug cos in good healthWith the new regulations set by the US FDA, the pathway to creating biosimilars will be both faster and more cost-effective. This developme...
- Dr Reddy's Laboratories jumps into the fray for Biogen's biosimilarsDr Reddy's Laboratories (DRL) and Intas Pharmaceuticals, both Indian companies, are reportedly in the race to acquire the biosimilar produc...
- Cipla, Kemwell Biopharma join hands to develop biosimilarsUnder the terms of the agreement, the joint venture will leverage Cipla and Kemwell’s complementary strengths for end-to-end product develo...
- 6 pharma stocks to bet on amid Covid 2.0"The private market has opened up for vaccination and Dr Reddy’s is likely to benefit from the sale of Sputnik-V vaccine."
- Cipla Gulf expands partnership with Alvotech for commercialisation of four drugs in Australia, New ZealandCipla Gulf FZ LCC is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia a...
- Cipla to invest Rs 590 crore for a biosimilars plant in South AfricaDrug firm Cipla will invest around Rand 1.3 billion (over Rs 590 crore) to launch a manufacturing facility in South Africa for the producti...
- Cipla to sell entire stake in Biomab Holding for $25,775,000Drug major Cipla has entered into an agreement to sell its entire stake in Biomab Holding to Biomab Brilliant for a consideration of $25,77...
- Hetero launches biosimilar Rituximab in IndiaHyderabad based Hetero pharma has launched biosimilar drug Rituximab under the brand name of MABALL, used in the treatment of blood cancer.
- Cipla partners with Hetero to launch biosimilar anaemia drugActorise is a biosimilar of 'Darbepoetin alfa', which is marketed by US-based Amgen under the brand Aranesp.
- Lobby fears norms violation in Cipla's biosimilar drugA lobby group of biotech drug companies in India has raised concerns about the approval of Cipla's first biosimilar drug Etanercept.
- Cipla launches biosimilar for rheumatic disorders in IndiaDrug major Cipla said it has launched biosimilar of Etanercept under the brand name 'Etacept' used for treatment of rheumatic disorders in ...
- Biotech drugs to replace chemical entities Lipitor & Plavix as market leadersThe global pecking order of blockbusters may soon be heading for a major upheaval with biotech drugs toppling the present market leaders.
- Cipla to invest about Rs 300 cr to acquire stakes in 2 cosDrug maker Cipla on Tuesday said it will invest USD 65 million (nearly Rs 300 crore) over the next three years with a Chinese joint venture...
- Cipla calls off marketing alliance with AvesthagenCipla has terminated its marketing agreement with Avesthagen and is looking at selling its 5.8% stake in the Bangalore-based company.
Load More
